Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
DVY vs IBB: how they differ
DVY and IBB hold 1% of their weight in the same names, and IBB returned more over the year.
iShares Select Dividend ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, DVY and IBB hold 1% of their money in the same securities at the same weight.
| Holding | DVY | IBB |
|---|---|---|
| GILEAD SCIENCES INC | 0.66% | 6.85% |
| Only in DVY | Only in IBB |
|---|---|
| ALTRIA GROUP INC 2.30% | Vertex Pharmaceuticals, Inc. 8.09% |
| PFIZER INC 2.22% | Amgen, Inc. 7.84% |
| T. ROWE PRICE GROUP INC 2.03% | Regeneron Pharmaceuticals, Inc. 4.91% |
| VERIZON COMMUNICATIONS INC 1.85% | Argenx SE 3.76% |
| PRUDENTIAL FINANCIAL INC 1.85% | Alnylam Pharmaceuticals, Inc. 3.12% |
| ONEOK INC 1.84% | Natera, Inc. 2.89% |
| HP INC 1.61% | Revolution Medicines, Inc. 2.78% |
| EDISON INTERNATIONAL 1.54% | Biogen, Inc. 2.47% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| DVY iShares Select Dividend ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | US dividend | Biotechnology |
| Total return, 1 year | +18.0% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +0.5 pts | +24.0 pts |
| Expense ratio | 0.38% | 0.44% |
| Already in the S&P 500 | 80.5% | 35.6% |
| Holdings | 100 | 248 |
DVY in plain words
DVY is an index equity fund tracking the US dividend. Over the year to Sep 11, 2026 it returned +18.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.38% a year. By its holdings filed for Apr 30, 2026, 80% of the fund by weight is stocks the S&P 500 also holds, across 100 positions, with the top ten at 18.3%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, DVY or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, DVY returned +18.0% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, DVY or IBB?
- DVY charges 0.38% a year and IBB charges 0.44%, so DVY is cheaper. Fees come from each fund's prospectus.
- How much do DVY and IBB overlap with the S&P 500?
- By their latest filed holdings, 80% of DVY and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, DVY against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/DVY-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources